Control of STDs - The role of prophylactic vaccines against herpes simplex virus

Sexually Transmitted Infections

Volumn 74, Issue 6, 1998, Pages 391-394

  Stanberry, L R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Genital herpes; Herpes simplex virus; Herpes vaccines

Indexed keywords

HERPES SIMPLEX VACCINE;

HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; INFECTION CONTROL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUALLY TRANSMITTED DISEASE; VACCINATION;

EID: 0032430119     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.74.6.391     Document Type: Review

References (40)

1. Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex viruses 1 and 2. In: Evans AS, Kaslow RA, eds. Viral infection of humans: epidemiology and control. 4th ed. New York: Plenum Press, 1997:419-54.
2. Kinghorn GR. Genital herpes: natural history and treatment of acute episodes, J Med Virol (Suppl) 1993;11:33-8.
3. Brugha R, Keersmaekers K, Renton A, et al. Genital herpes infection: a review, Int J Epidemiol 1997;26:698-709.
4. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
5. Stanberry LR, Kern ER, Richards JT, et al. Genital herpes in guinea pigs: pathogenesis of the primary infection and the description of recurrent disease. J Infect Dis 1982;146:397 404.
6. Stanberry LR. The pathogenesis of herpes simplex virus infections. In: Stanberry LR, ed. Genital and neonatal herpes. Chichester: John Wiley, 1996:31-48.
7. Stanberry LR, Bernstein DI, Burke RL, et al. Recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155: 914-20.
8. Bourne N, Stanberry LR, Bernstein DI, et al. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996;173:800-7.
9. Da Costa XJ, Bourne N, Stanberry LR, et al. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology 1997;232:1-12.
10. Meignier B, Longnecker R, Roizman R. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;58:602-14.
11. Stanberry LR, Myers MG, Stephanopoulos DI, et al. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy. J Med Virol 1989;70:3177-85.
12. Gallichan WS, Johnson DC, Graham FL, et al. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J Infect Dis 1993;168:622-9.
13. Heineman TC, Connelly BL, Bourne N, et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995;69:8109-13.
14. Erturk M, Phillpotts RJ, Welch MJ, et al. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection. Vaccine 1991;9:728-34.
15. McClements WL, Armstrong ME, Keys RD, et al. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Nati Acad Sci USA 1996;93:11414-20.
16. Kriesel JD, Spruance SL, Daynes RA, et al. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease. J Infect Dis 1996;173:536-41.
17. Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997;175:16-25.
18. Pachuk CJ, Arnold R, Herold K, et al Humoral and cellular immune responses to herpes simplex virus-2 glycoprotein D generated by facilitated DNA immunization of mice. Curr Top Microbiol Immunol 1998,226:79-89.
19. Stanberry LR, Kit S, Myers MG. Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. J Virol 1985;55:322-8.
20. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998;160:6093-100.
21. Kuklin NA, Daheshia M, Chun S, et al. Role of mucosal immunity in herpes simplex virus infection. J Immunol 1998;160:5998-6003.
22. Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998;177:1155-61.
23. Skinner GRB, Woodman C, Hartley C, et al. Preparation and immunogenicity of vaccine Ac NFU, (S)MRC towards prevention of herpes genitalis. BrJ Vener Dis 1982; 58:381-6.
24. Skinner GRB, Fink C, Melling J, et al. Report of twelve years' experience in open study of Skinner herpes simplex vaccine towards the prevention of herpes genitalis. Med Microbiol Immunol 1992;180:305-20.
25. Cappel R. Sprecher S, Rickaert F, et al. Immune response to a DNA-free herpes simplex virus vaccine in man. Arch Virol 1982;73:61-7.
26. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990;161:653-60. -
27. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol 1992;179: 137-5 8.
28. Stanberry LR. Herpes immunization-on the threshold. J Europ Acad Dermatol Venereol 1996;7:120-8.
29. Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med 1995;122:889-98.
30. Leroux-Roels G, Moreau E, Desombre I, et al. Persistence of humoral and cellular immune responses and booster effect following vaccination with herpes simplex (gD2) candidate vaccine with MPL. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994:205 (abstract H57).
31. Fleck M, Podlech J, Weise K, et al. A vaccinia virus - herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome HSV type 2 induced humoral immunosuppression and protect against viral challenge. Med Microbiol Immunol 1994;183:87-94.
32. Chabalgoity JA, Khan CM, Nash AA, et al. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol Microbiol 1996;19:791-801.
33. Karem KL, Bowen J, Kuklin N, et al. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 1997; 78:427-34.
34. Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1 : sites of immune intervention in pathogenesis of challenge virus infection. J Viral 1994;68:689-96.
35. Farrel HE, McLean CS, Harley, et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Viral 1994;68:927-32.
36. Hickling JK, Chrisholm SE, Duncan IA et al. Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in phase I clinical trials in HSV-2 seropositive and seronegative volunteers. Abstracts of the 8th International Congress on Infectious Diseases. Boston, Massachusetts, May 1998, Abstract 22.008, p 89.
37. Roberts JSC, Uttridge JA, Hickling JK, et al. Safety tolerability and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase 1 clinical trials in HSV-2 seropositive and seronegative volunteers. Abstracts of the 8th International Congress on Infectious Diseases. Boston, Massachusetts, May 1998, Abstract 22.009, p 89.
38. Spector FC, Kern ER, Palmer J, et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 1998;177:1143-54.
39. Rouse BT, Nair S, Rouse RJ, et al. DNA vaccines and immunity to herpes simplex virus. Curr Top Microbiol Immunol 1998;226:69-78.
40. Bourne N, Milligan GN, Schleiss MR, et al. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996;14:1230-4.